Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (241-250 of 437) with videos related to

Pageof 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2023
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150René Bruno, Mathilde Marchand, Kenta Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
Journal for Immunotherapy of Cancer|February 22, 2022
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trialHoward Jack West, Mark McCleland, Federico Cappuzzo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150René Bruno, Mathilde Marchand, Kenta Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline UpdateGregory P Kalemkerian, Navneet Narula, Erin B Kennedy, et al.
Clinical Epigenetics|February 18, 2021
DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancerTorsten Goldmann, Bernhard Schmitt, Julia Müller, et al.
Translational Lung Cancer Research|December 10, 2025
High GLUT1 protein expression is associated with unfavorable tumor features and poor prognosis in non-small cell lung cancerBirgit Hantzsch-Kuhn, Nina Schraps, Martin Reck, et al.
Pageof 44

Showing results (241-250 of 437) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2023
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150René Bruno, Mathilde Marchand, Kenta Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2014
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancerSilvia Novello, Rolf Kaiser, Anders Mellemgaard, et al.
Journal for Immunotherapy of Cancer|February 22, 2022
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trialHoward Jack West, Mark McCleland, Federico Cappuzzo, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 3, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150René Bruno, Mathilde Marchand, Kenta Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)Egbert F Smit, Yi-Long Wu, Radj Gervais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline UpdateGregory P Kalemkerian, Navneet Narula, Erin B Kennedy, et al.
Clinical Epigenetics|February 18, 2021
DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancerTorsten Goldmann, Bernhard Schmitt, Julia Müller, et al.
Translational Lung Cancer Research|December 10, 2025
High GLUT1 protein expression is associated with unfavorable tumor features and poor prognosis in non-small cell lung cancerBirgit Hantzsch-Kuhn, Nina Schraps, Martin Reck, et al.
Pageof 44